These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6343234)

  • 1. Complement-mediated killing of myeloma tumour cells: differences in susceptibility to lysis by antibodies and complement are independent of antigen expression and antibody binding.
    Celis B; Celis E
    Immunology; 1983 Jun; 49(2):321-8. PubMed ID: 6343234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of antigen density on complement-mediated lysis, T-cell-mediated killing, and antigenic modulation.
    Lesley J; Hyman R; Dennert G
    J Natl Cancer Inst; 1974 Dec; 53(6):1759-65. PubMed ID: 4140238
    [No Abstract]   [Full Text] [Related]  

  • 3. Susceptibility of mammary tumor cells to complement-mediated cytolysis after in vitro or in vivo fatty acid manipulation.
    Erickson KL; Thomas IK
    J Natl Cancer Inst; 1985 Aug; 75(2):333-40. PubMed ID: 3860685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of immune lysis. I. Physiological distinction between target cell death mediated by cytotoxic T lymphocytes and antibody plus complement.
    Russell JH; Masakowski VR; Dobos CB
    J Immunol; 1980 Mar; 124(3):1100-5. PubMed ID: 6965686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of natural antibodies in normal rabbit serum with similar specificity pattern as mouse natural killer cells.
    Grönberg A; Hansson M; Kiessling R; Andersson B; Kärre K; Roder J
    J Natl Cancer Inst; 1980 May; 64(5):1113-9. PubMed ID: 6966004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis. II. Relationship to redistribution of the antigen.
    Gordon J; Stevenson GT
    Immunology; 1981 Jan; 42(1):13-7. PubMed ID: 6970171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface antigen expressed in hematopoietic cells derived from Fv-4r mouse strains.
    Yoshikura H; Odaka T
    J Natl Cancer Inst; 1982 Jun; 68(6):1005-9. PubMed ID: 6283223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
    Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
    Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies specific to surface antigens are not effective in complement-mediated killing of Haemophilus ducreyi.
    Frisk A; Ahmed HJ; Van Dyck E; Lagergård T
    Microb Pathog; 1998 Aug; 25(2):67-75. PubMed ID: 9712686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of antibody and complement in the cellular response to Trypanosoma congolense.
    Schmitz B; Gehrung M; Thornton M; Speth V
    Clin Exp Immunol; 1984 Apr; 56(1):73-80. PubMed ID: 6713731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immune killing of nucleated cells: mechanisms of complement-mediated attack and target cell defense.
    Ohanian SH; Schlager SI
    Crit Rev Immunol; 1981 Jan; 1(3):165-209. PubMed ID: 6174273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgG pair formation on one antigenic molecule is the main mechanism of synergy between antibodies in complement-mediated lysis.
    Hughes-Jones NC; Gorick BD; Miller NG; Howard JC
    Eur J Immunol; 1984 Nov; 14(11):974-8. PubMed ID: 6209148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
    Fuji H
    Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermia enhancement of antibody-complement cytotoxicity for human colon tumor cells.
    Tompkins WA; Rama Rao GV; Pantasatos P; Cain CA
    J Natl Cancer Inst; 1981 Mar; 66(3):453-9. PubMed ID: 6937702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-enhanced modulation of cell surface antigens: effect on immune lytic susceptibility.
    Catanzaro PJ; Brandt WE; Hogrefe WR; Phillips SM; Top FH
    J Immunol; 1976 Oct; 117(4):1104-10. PubMed ID: 61990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells.
    Hakulinen J; Meri S
    Lab Invest; 1994 Dec; 71(6):820-7. PubMed ID: 7528832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell growth-dependent variation in the sensitivity of human and mouse tumor cells to complement-mediated killing.
    Ohanian SH; Yamazaki M; Schlager SI; Faibisch M
    Cancer Res; 1983 Feb; 43(2):491-5. PubMed ID: 6401218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific lysis of Plasmodium yoelii infected mouse erythrocytes with antibody and complement.
    Gabriel J; Berzins K
    Clin Exp Immunol; 1983 Apr; 52(1):129-34. PubMed ID: 6861370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
    Mäenpää A; Junnikkala S; Hakulinen J; Timonen T; Meri S
    Am J Pathol; 1996 Apr; 148(4):1139-52. PubMed ID: 8644856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins.
    Tedesco F; Narchi G; Radillo O; Meri S; Ferrone S; Betterle C
    J Immunol; 1993 Aug; 151(3):1562-70. PubMed ID: 7687635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.